[小细胞肺癌维持治疗的研究进展]
[Research Progression of Maintenance Therapy in Small Cell Lung Cancer].
作者信息
Lu Yunyun, Fan Yun
机构信息
Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou 310053, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2015 Sep 20;18(9):559-64. doi: 10.3779/j.issn.1009-3419.2015.09.06.
Abstract
Lung cancer is one of the common malignant tumors in the world, the incidence of small cell lung cancer is about 15% among them. Small cell lung cancer is highly sensitive to first-line chemotherapy, but most of the patients relapse after the first-line therapy quickly. Despitemany clinical researchof chemotherapy, biological agents and molecular targeting agents since the 1980s, there still remains a substantial lack of consensus regarding the appropriate therapeutic management on maintenance therapy of small cell lung cancer. The review focuses on maintenance therapy of small cell lung cancer.
摘要
肺癌是全球常见的恶性肿瘤之一，其中小细胞肺癌的发病率约为15%。小细胞肺癌对一线化疗高度敏感，但大多数患者在一线治疗后很快复发。自20世纪80年代以来，尽管对化疗、生物制剂和分子靶向药物进行了许多临床研究，但在小细胞肺癌维持治疗的适当治疗管理方面仍存在很大的共识缺乏。本文综述聚焦于小细胞肺癌的维持治疗。
相似文献
1
[Research Progression of Maintenance Therapy in Small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2015 Sep 20;18(9):559-64. doi: 10.3779/j.issn.1009-3419.2015.09.06.
2
[Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):806-810. doi: 10.3779/j.issn.1009-3419.2020.102.19. Epub 2020 Aug 5.
3
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Ann Oncol. 2018 Oct 1;29(10):2076-2084. doi: 10.1093/annonc/mdy326.
4
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.
5
Tumor cell plasticity and intrinsic immunogenicity: Implications for immunotherapy resistance in small-cell lung cancer.
Thorac Cancer. 2021 Oct;12(19):2523-2525. doi: 10.1111/1759-7714.14117. Epub 2021 Aug 31.
6
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.
Clin Lung Cancer. 2016 Sep;17(5):334-340. doi: 10.1016/j.cllc.2016.05.008. Epub 2016 Jun 2.
7
Second-line treatments of small-cell lung cancers.
Expert Rev Anticancer Ther. 2017 Nov;17(11):1033-1043. doi: 10.1080/14737140.2017.1372198. Epub 2017 Sep 8.
8
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Br J Cancer. 2018 Mar 6;118(5):648-653. doi: 10.1038/bjc.2017.465. Epub 2018 Jan 30.
9
Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Oncology. 2020;98(11):749-754. doi: 10.1159/000508516. Epub 2020 Jul 14.
10
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
引用本文的文献
1
Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis.
Front Oncol. 2020 May 28;10:868. doi: 10.3389/fonc.2020.00868. eCollection 2020.
本文引用的文献
1
Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.
J Transl Med. 2015 May 13;13:158. doi: 10.1186/s12967-015-0514-0.
2
Chinese herbal decoction based on syndrome differentiation as maintenance therapy in patients with extensive-stage small-cell lung cancer: an exploratory and small prospective cohort study.
Evid Based Complement Alternat Med. 2015;2015:601067. doi: 10.1155/2015/601067. Epub 2015 Mar 1.
3
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.
4
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Ann Oncol. 2015 May;26(5):908-914. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.
5
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
Invest New Drugs. 2014 Apr;32(2):362-8. doi: 10.1007/s10637-013-0061-6. Epub 2014 Jan 15.
6
Long survival of a small-cell lung cancer patient who received maintenance chemotherapy with irinotecan.
Case Rep Oncol. 2013 Nov 14;6(3):569-73. doi: 10.1159/000356826. eCollection 2013.
7
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.
8
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Lung Cancer. 2012 Aug;77(2):359-64. doi: 10.1016/j.lungcan.2012.03.009. Epub 2012 May 3.
9
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3.
10
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
J Clin Oncol. 2011 Jun 1;29(16):2215-22. doi: 10.1200/JCO.2010.29.3423. Epub 2011 Apr 18.
Zotero 插件